RxDoctor Payments Data

Christopher Cain

Family · Erie, PANPI 1598236325

Payments from drug & device makers

$337in general payments, 2019–2025

Across 18 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$69
  • Alkermes, Inc.$40
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$39
  • Lilly USA, LLC$36
  • Novo Nordisk$36
  • AbbVie$20
  • plus $98 from 6 others

What the payments were for

  • Food & beverage$337100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$337 in reported general payments places this provider in the 50th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$428
Medicare patients
31
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide232$256,950
JardianceEmpagliflozin53$81,776
EliquisApixaban27$35,816
OzempicSemaglutide34$31,753
XareltoRivaroxaban24$29,355
FarxigaDapagliflozin Propanediol20$28,827
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$22,885
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$18,295
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$16,878
Spiriva RespimatTiotropium Bromide25$15,619
JanuviaSitagliptin Phosphate11$15,344
Humalog Kwikpen U-100Insulin Lispro21$8,684
VascepaIcosapent Ethyl15$8,115
SymbicortBudesonide/Formoterol Fumarate28$8,055
Breo ElliptaFluticasone/Vilanterol18$7,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$36$256,950232 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$14$47,63669 claims
AstraZenecaFarxiga, Symbicort$16$36,88248 claims
PfizerEliquis$15$35,81627 claims
Novo NordiskOzempic$36$31,75334 claims
MerckJanuvia$19$15,34411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,717 family providers in Pennsylvania.

Other family in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →